CV Protection: Is It Achievable in Patients with T2DM?
PROGRAM DESCRIPTION According to 2014 data from the Centers for Disease Control and Prevention, 29.1 million individuals, or 9.3% of the US population, have type 2 diabetes mellitus (T2DM). Death …
According to 2014 data from the Centers for Disease Control and Prevention, 29.1 million individuals, or 9.3% of the US population, have type 2 diabetes mellitus (T2DM). Death from cardiovascular (CV) disease is 70% higher in adults with diabetes compared to those without diabetes, and patients with diabetes have a decreased life expectancy, mostly due to premature CV death.Evidence is accumulating that other factors besides impaired glucose metabolism play a role in the pathophysiology of T2DM and that a comprehensive approach against insulin resistance, obesity, hypertension, and dyslipidemia in addition to diet and exercise is required. In addition, because certain pharmacologic therapies were found to increase the risk of CV events, all new drugs introduced since 2008 have been mandated by the FDA to undergo CV safety outcome trials (CVOT) in high-risk T2DM patients. As a result, a growing body of evidence is accumulating on the ability of certain drugs to reduce CV mortality, overall mortality, and hospitalizations for worsening heart failure in high-risk patients with T2DM. This activity will review the prevalence of CV comorbidities in T2DM patients, present new data on the results of recent CVOTs, and discuss approaches to treatment that is targeted to maximizing outcomes in the T2DM patient with CVD.
Upon completion of this activity, participants should be able to:Describe the prevalence of CVD among patients with T2DMOutline the benefits and risks of SGLT2 inhibitors and GLP1-RAs in T2DM patients as demonstrated in current and emerging CV outcomes trialsIdentify a logical addition to existing antihyperglycemic treatment for T2DM patients based on evidence based guidelines, benefits and risks of second-line antihyperglycemic treatments, and patient profiles and preferences
I'm interested in this
Share with others
Write the first review
Share with others